DOCKET NO.: A0848.70004US00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Silence et al. Serial No.: 10/534,292 Confirmation No.: 1144

Filed: May 9, 2005

For: CAMELIDAE ANTIBODIES AGAINST

IMMINOGLOBULIN E AND USE THEREOF FOR THE

TREATMENT OF ALLERGIC DISORDERS

Examiner: Michael Edward Szperka

Art Unit: 1644

## MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR \$\$1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

# PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

## PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references. Serial No.: 10/534,292 -2 - Art Unit: 1644

Conf. No.: 1144

# PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following are remarks concerning the other information cited:

An English language Abstract is provided for Japanese Publication No. JP 62175426 A (Cite No. B19 on Form PTO-1449).

### PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

Conf. No.: 1144

An early and favorable action is hereby requested.

Respectfully submitted,

By: John P. Van Amsterdam Ph D

John R. Van Amsterdam, Ph.D. Reg. No. 40,212

Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: A0848.70004US00

Date: June 4, 2007

xNDDx

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.:	10/534,292	ATTY. DOCKET NO.: A0848.70004US00	
INFORMATION DISCLOSURE	FILING DATE:	May 9, 2005	CONFIRMATION NO.: 1144	
STATEMENT BY APPLICANT	APPLICANT:	Silence et al.		
Sheet 1 of 1	GROUP ART UNIT:	1644	EXAMINER: Michael Edward Szperka	

### U.S. PATENT DOCUMENTS

	Cite	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication or Issue	
	No.	Number	Kind Code	Document Document	of Cited Document MM-DD-YYYY	
	A8	2002/0165387	A1	Kerr Anderson et al.	11-07-2002	
	A9	2002/0001587	A1	Erickson et al.	01-03-2002	

#### FOREIGN PATENT DOCUMENTS

Examiner's	Cite No.	Foreign Patent Document		ent		Date of	
Initials #		Office/ Country	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
	B19	JP	62175426	Α	Shimizu Kazufumi	08-01-1987	Abstract
				i l			

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

		OTHER ART — NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C15	WORLEDGE K.L. et al., "Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats," <i>Digestive Diseases and Sciences</i> December 2000; 45(12): 2298-2305	
	C16	TEITELBAUM R. et al., "A mAB recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival," Proc. Natl. Acad. Sci. USA December 1998; 95(26): 15688-15693	
	C17	SKURKOVICH S. et al., "Treatment of corneal transplant rejection in humans with anti-interferon- gamma antibodies," <i>American Journal of Ophthalmology</i> June 2002; 133(6): 829-830	
	C18	SHIMAMOTO C. et al., "Inhibition of Helicobacter pylori infection by orally administered yolk-derived anti-Helicobacter pylori antibody," Database Biosis Biosciences Information Service, Philadelphia, PA LIS-May 2002	Abstract

EXAMINER:	DATE CONSIDERED:

[NOTE - No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR § 1.98 and 1287OG163. Copies of all other patent(s), publication, for imaging U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 1.98, and 2) the earlier application is relicted upon for an earlier filing date under 35 U.S.C. § 12.01

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or noteitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<sup>\*</sup>a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).